Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurocritical Care
Published in: Neurocritical Care 1/2010

01-02-2010 | Translational Research

Arginine-Vasopressin V1 but not V2 Receptor Antagonism Modulates Infarct Volume, Brain Water Content, and Aquaporin-4 Expression Following Experimental Stroke

Authors: Xiaoqin Liu, Shin Nakayama, Mahmood Amiry-Moghaddam, Ole Petter Ottersen, Anish Bhardwaj

Published in: Neurocritical Care | Issue 1/2010

Login to get access

Abstract

Background

Aquaporin-4 (AQP4) plays an important role in the evolution of ischemia-evoked cerebral edema. Experimental studies have also demonstrated anti-edema effects of arginine-vasopressin (AVP) antagonists. In a well-characterized murine model of ischemic stroke, we tested the hypotheses that treatment with selective AVP V1 but not V2 receptor antagonist (1) attenuates injury volume and ischemia-evoked cerebral edema; and (2) modulates ischemia-evoked AQP4 expression.

Methods

Isoflurane-anesthetized adult male C57bl/6 mice were subjected to 60 min of middle cerebral artery occlusion (MCAO) by the intraluminal suture technique. Adequacy of MCAO and reperfusion was monitored with laser-Doppler flowmetry over the ipsilateral parietal cortex. Mice were treated with intracerebroventricular injection of selective AVP V1 and V2 receptor antagonist or control vehicle (0.9% saline). Infarct volume (tetrazolium staining), cerebral edema (wet-to-dry ratios) and AQP4 protein expression (immunoblotting) were determined in different treatment groups in separate sets of experiments at 24 h of reperfusion.

Results

Infarct volume (percentage of contralateral structure; mean ± SEM) was significantly attenuated in mice treated with 500 ng V1 receptor antagonist as well as at a dose of 1000 ng compared to controls. However, there was no difference in infarct volume following treatment with 1000 ng V2 antagonist as compared to controls. Water content in the ischemic hemisphere was significantly attenuated with V1 receptor antagonist (1000 ng) but not with V2 receptor antagonist as compared to controls. Treatment with AVP V1 receptor antagonist (1000 ng) but not V2 receptor antagonist, significantly upregulated AQP4 protein expression (% β-actin) compared to saline-treated mice in ipsilateral (ischemic) cerebral cortex.

Conclusions

These data demonstrate that following experimental stroke AVP V1 receptor antagonism: (1) attenuates injury volume and ischemia-evoked cerebral edema; (2) modulates AQP4 expression; and (3) may serve as an important therapeutic target for neuroprotection and ischemia-evoked cerebral edema.
Literature
1.
Landgraf R. Central release of vasopressin: stimuli, dynamics, consequences. Prog Brain Res. 1992;91:29–39.CrossRefPubMed
2.
Buijs RM. Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Cell Tissue Res. 1978;192:423–35.CrossRefPubMed
3.
Riphagen CL, Pittman QJ. Arginine vasopressin as a central neurotransmitter. Fed Proc. 1986;45:125–32.
4.
Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol. 2006;59:229–36.CrossRefPubMed
5.
Chang Y, Chen T-Y, Chen C-H, et al. Plasma arginine-vasopressin following experimental stroke: effect of osmotherapy. J Appl Physiol. 2006;100:1445–51.CrossRefPubMed
6.
Niermann H, Amiry-Moghaddam M, Holthoff K, et al. A novel role of vasopressin in the brain: modulation of activity-dependent water flux in the neocortex. J Neurosci. 2001;21:3045–51.PubMed
7.
Depasquale M, Patlak CS, Cserr HF. Brain ion and volume regulation during acute hyponatremia in Battleboro rats. Am J Physiol. 1989;256:F1059–66.PubMed
8.
Cserr HF, Latzkovitz L. A role for centrally-released vasopressin in brain ion and volume regulation: a hypothesis. Prog Brain Res. 1992;91:3–6.CrossRefPubMed
9.
Fernandez N, Martinez MA, Garcia-Villalon AL, et al. Cerebral vasoconstriction produced by vasopressin in conscious goats: role of vasopressin V(1) and V(2) receptors and nitric oxide. Br J Pharmacol. 2001;132:1837–44.CrossRefPubMed
10.
Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–32.CrossRefPubMed
11.
Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1—receptor physiology. Crit Care. 2003;7:427–34.CrossRefPubMed
12.
Kozniewska E, Szczepanska-Sadowska E. V2-like receptors mediate cerebral blood flow increase following vasopressin administration in rats. J Cardiovasc Pharmacol. 1990;15:579–85.PubMed
13.
Vakili A, Kataoka H, Plesnila N. Role of arginine vasopressin V1 and V2 receptors for brain damage after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:1012–9.CrossRefPubMed
14.
Barreca T, Gandolfo C, Corsini G, et al. Evaluation of the secretory pattern of plasma arginine vasopressin in stroke patients. Cerebrovasc Dis. 2001;11:113–8.CrossRefPubMed
15.
Dickinson LD, Betz AL. Attenuated development of ischemic brain edema in vasopressin-deficient rats. J Cereb Blood Flow Metab. 1992;12:681–90.PubMed
16.
Liu XF, Shi YM, Lin BC. Mechanism of action of arginine vasopressin on acute ischemic brain edema. Chin Med (Engl). 1991;104:490–3.
17.
Ikeda Y, Toda S, Kawamoto T, Teramoto A. Arginine vasopressin release inhibitor RU51599 attenuates brain edema following transient forebrain ischemia in rats. Acta Neurochir (Wien). 1997;139:1166–71.CrossRef
18.
Shuiab A, Xu WC, Yang T, Noor R. Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in a focal embolic stroke model. Stroke. 2002;33:3033–7.CrossRef
19.
Kleindienst A, Fazzina G, Dunbar JG, et al. Protective effect of the V1a receptor antagonist SR49059 on brain edema formation following middle cerebral artery occlusion in the rat. Acta Neurochir Suppl. 2006;96:303–6.CrossRefPubMed
20.
King LS, Agre P. Pathophysiology of the aquaporin water channels. Annu Rev Physiol. 1996;58:619–48.CrossRefPubMed
21.
Manley GT, Fujimura M, Ma T, et al. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat Med. 2000;6:159–63.CrossRefPubMed
22.
Badaut J, Lasbennes F, Magistretti PJ, et al. Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab. 2002;22:367–78.CrossRefPubMed
23.
Amiry-Moghaddam M, Otsuka T, Hurn PD, et al. An α-syntrophin dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc Natl Acad Sci USA. 2003;100:2106–11.CrossRefPubMed
24.
Amiry-Moghaddam M, Ottersen OP. The molecular basis of water transport in the brain. Nat Rev Neurosci. 2003;4:991–1001.CrossRefPubMed
25.
Amiry-Moghaddam M, Xue R, Haug F-M, et al. Alpha-syntrophin deletion removes the perivascular but not endothelial pool of aquaporin-4 at the blood–brain barrier and delays the development of brain edema in an experimental model of acute hyponatremia. FASEB J. 2004;18:542–4.PubMed
26.
Bloch O, Papadopoulos MC, Manley GT, et al. Aquaporin-4 gene deletion in mice increases focal edema associated with staphylococcal brain abscess. J Neurochem. 2005;95:254–62.CrossRefPubMed
27.
Papadopoulos MC, Manley GT, Krishna S, et al. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291–3.PubMed
28.
Ribeiro Mde C, Hirt L, Bogousslavsky J, et al. Time course of aquaporin expression after transient focal cerebral ischemia in mice. J Neurosci Res. 2006;83:1231–40.CrossRefPubMed
29.
Frigeri A, Grooper MA, Umenishi F, et al. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J Cell Sci. 1995;108:2993–3002.PubMed
30.
Nielsen S, Nagelhus EA, Amiri-Moghaddam M, et al. Specialized membrane domains for water transport in glial cells: high resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997;17:171–80.PubMed
31.
Sawada M, Alkayed NJ, Goto S, et al. Estrogen receptor antagonist ICI182, 780 exacerbates ischemic injury in female mouse. J Cereb Blood Flow Metab. 2000;20:112–8.CrossRefPubMed
32.
Zeynalov E, Chen CH, Froehner SC, et al. The perivascular pool of aquaporin-4 mediates the effect of osmotherapy in postischemic cerebral edema. Crit Care Med. 2008;36:2634–40.CrossRefPubMed
33.
Liu X, Zhang W, Alkayed NJ, et al. Lack of sex-linked differences in cerebral edema and aquaporin-4 expression after experimental stroke. J Cereb Blood Flow Metab. 2008;28:1898–906.CrossRefPubMed
34.
Hara H, Huang PL, Panahian N, et al. Reduced brain edema and infarction volume in mice lacking the neuronal isoform of nitric oxide synthase after transient MCA occlusion. J Cereb Blood Flow Metab. 1996;16:605–11.CrossRefPubMed
35.
Lin TN, He YY, Wu G, et al. Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. Stroke. 1993;24:117–21.PubMed
36.
Ouyang Y, Rosenstein A, Kreiman G, et al. Tetanic stimulation leads to increased accumulation of Ca(2+)/calmodulin-dependent protein kinase II via dendritic protein synthesis in hippocampal neurons. J Neurosci. 1999;15(19):7823–33.
37.
Frydenlund DS, Bhardwaj A, Otsuka T, et al. Temporary loss of perivascular aquaporin-4 in neocortex after transient middle cerebral artery occlusion in mice. Proc Natl Acad Sci USA. 2006;103:13532–6.CrossRefPubMed
38.
Hacke W, Schwab S, Horn M, et al. “Malignant” middle cerebral artery infarction: clinical course and prognostic signs. Arch Neurol. 1996;53:309–15.PubMed
39.
40.
Abe O, Okubo T, Hayashi N, et al. Temporal changes of apparent diffusion coefficients of water and metabolites in rats with hemispheric infarction; experimental study of transhemispheric diaschisis in the contralateral hemisphere at 7 tesla. J Cereb Blood Flow Metab. 2000;20:726–35.CrossRefPubMed
41.
Abbott NJ. Inflammatory mediators and modulation of blood–brain barrier permeability. Cell Mol Neurobiol. 2000;20:131–47.CrossRefPubMed
42.
Bemana I, Nagao S. Treatment of brain edema with nonpeptide arginine vasopressin V1 receptor antagonist OPC-21268 in rats. Neurosurgery. 1999;44:148–54.CrossRefPubMed
43.
Van Bruggen N, Thibodeaux H, Palmer JT, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion in mouse brain. J Clin Invest. 1999;104:1613–20.CrossRefPubMed
44.
Doczi T, Laszlo FA, Szerdahelyi P, Joo F. Involvement of vasopressin in brain edema formation: further evidence obtained from the Battleboro diabetes insipidus rat with subarachnoid hemorrhage. Neurosurgery. 1984;14:436–41.PubMedCrossRef
45.
Trabold R, Krieg S, Scholler K, et al. Role of vasopressin v(1a) and v(2) receptors for the development of secondary brain damage after traumatic brain injury in mice. J Neurotrauma. 2008;25:1459–65.CrossRefPubMed
46.
Rosenberg GA, Scremin O, Estrada E, et al. Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats. Stroke. 1992;23:1767–73.PubMed
47.
Molnár AH, Varga C, Berkó A, et al. Prevention of hypoxic brain oedema by the administration of vasopressin receptor antagonist OPC-31260. Prog Brain Res. 2008;170:519–25.CrossRefPubMed
48.
Liu X, Jin Y, Zheng H, Chen G, et al. Arginine vasopressin gene expression in supraoptic nucleus and paraventricular nucleus of hypothalamus following cerebral ischemia and reperfusion. Chin Med Sci J. 2000;15:157–61.PubMed
49.
Reeder RF, Nattie EE, North WG. Effect of vasopressin on cold-induced brain edema in cats. J Neurosurg. 1986;64:941–50.CrossRefPubMed
50.
Liu X, Jin Y, Chen G. Effect of vasopressin on delayed neuronal damage in hippocampus following cerebral ischemia and reperfusion in gerbils. Chin Med Sci J. 1996;11:93–6.PubMed
51.
Latzkovitz L, Cserr HF, Park JT, et al. Effects of arginine vasopressin and atriopeptin on glial cell volume measured as 3-MG space. Am J Physiol. 1993;264:C603–8.
52.
Urban IJ, Killian MJ. Two actions of vasopressin on neurons in the rat ventral hippocampus; a microelectrophoretic study. Neuropeptides. 1990;16:83–90.CrossRefPubMed
53.
Fields JD, Bhardwaj A. Non-peptide arginine-vasopressin antagonists (vaptans) for the treatment of hyponatremia in neurocritical care: a new alternative? Neurocrit Care. 2009;37:2306–7.
54.
Okuno K, Taya K, Marmarou CR, et al. The modulation of aquaporin-4 by using PKC-activator (phorbol myristate acetate) and V1a receptor antagonist (SR49059) following middle cerebral artery occlusion/reperfusion in the rat. Acta Neurochir Suppl. 2008;102:431–6.CrossRefPubMed
55.
Taya K, Gulsen S, Okuno K, et al. Modulation of AQP4 expression by the selective V1a receptor antagonist, SR49059, decreases trauma-induced brain edema. Acta Neurochir Suppl. 2008;102:425–9.CrossRefPubMed
56.
Vajda Z, Pedersen M, Füchtbauer EM, et al. Delayed onset of brain edema and mislocalization of aquaporin-4 in dystrophin-null transgenic mice. Proc Natl Acad Sci USA. 2002;99:13131–6.CrossRefPubMed
Metadata
Title
Arginine-Vasopressin V1 but not V2 Receptor Antagonism Modulates Infarct Volume, Brain Water Content, and Aquaporin-4 Expression Following Experimental Stroke
Authors
Xiaoqin Liu
Shin Nakayama
Mahmood Amiry-Moghaddam
Ole Petter Ottersen
Anish Bhardwaj
Publication date
01-02-2010
Publisher
Humana Press Inc
Published in
Neurocritical Care / Issue 1/2010
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-009-9277-x

Other articles of this Issue 1/2010

Neurocritical Care 1/2010 Go to the issue

Practical Pearl

Acute Granulomatous Acanthamoeba Encephalitis in an Immunocompetent Patient

Original Article

Does Stimulus Rate Matter When Performing Somatosensory Evoked Potentials for Coma Patients?

Practical Pearl

Intracranial Hemorrhage Following Thrombolytic Use for Stroke Caused by Infective Endocarditis

Original Article

Brain Tissue Oxygenation in Children Diagnosed With Brain Death

Original Article

Phenylephrine but not Ephedrine Reduces Frontal Lobe Oxygenation Following Anesthesia-Induced Hypotension

Original Article

Effect of Shivering on Brain Tissue Oxygenation During Induced Normothermia in Patients With Severe Brain Injury